Skip to main content

Table 1 Summary of key input data for Haiti in 2002(All costs in US dollars)

From: Impact of DOTS expansion on tuberculosis related outcomes and costs in Haiti

EPIDEMIOLOGIC/PROGRAMME DATA

HAITI

REFERENCE/SOURCE

 

Population (2002)

8.3 million

[9]

Gross National Income annual per capita (US$)

$ 440

[9]

Life expectancy at birth

52.0

[9]

All cause mortality

Age specific

[44]

Incidence new smear positive TB per 100,000 (2001)

138

[8]

Annual risk of TB infection (ARI)

2.26%

Calculated from [14] and [8]

Prevalence of LTBI at age 20

41%

Calculated from [14]

Likelihood of diagnosis and treatment of LTBI

1%

[59] *

Completion of LTBI Treatment

67%

[60]

Efficacy of 9 INH – INH Sensitive

90%

[61]

INH Resistant

0

[62]

Prevalence of HIV infection – 2002

4.5%

[10]

Incidence of HIV infection

0.46%/year

Calculated from [35]

DOTS Coverage – 2002

37%

[11]

Case detection rate – 2001

49%

[8]

Drug Resistance

   

   Single drug resistance

20% (11%-31%)

[12]

   Multi drug resistance (HR)

0.3% (0–4%)

[12;63]

Treatment outcomes New cases – 2001

Overall [8]

DOTS areas (NTP)

Non-DOTS

   Cure/complete

71%

85%

63%

   Default/transfer/not evaluated

23%

9%

31%

   Die

5%

5%

5%

   Fail

1%

1%

1%

Outcomes Re-treatment cases – 2001

Overall [8]

DOTS areas (NTP)

Non-DOTS

   Cure/complete

54%

80%

39%

   Default/transfer/not evaluated

29%

4%

44%

   Die

8%

8%

8%

   Fail

8%

8%

8%

  1. Notes:
  2. * – This assumes only dually infected (HIV and TB infection) whose HIV infection is detected and are tuberculin tested at a limited number of screening centres will be treated.
  3. NTP – data on treatment outcomes in areas with DOTS, from cohort reports to National TB programme